Our Science

Lytix Biopharma has developed a groundbreaking oncolytic molecule platform designed for intratumoral injection, that overcomes the limitations of current immunotherapies and delivers durable anti-tumor responses.

The Challenge

Most Patients Won't Respond to Immune Checkpoint Inhibitors

Immune checkpoint inhibitors have revolutionized cancer treatment, but many patients fail to respond. This lack of response is driven by three key factors:

Acquired Resistance

Immunotherapy resistance from multiple lines of treatment limits patient response

Tumor Heterogeneity

Tumor heterogeneity and low mutational burden reduce checkpoint inhibitor efficacy

Limited T-cell Infiltration

Low PD-L1 expression and limited T-cell infiltration of the tumor microenvironment

Our Solution

Our Oncolytic Molecule Therapies Address These Limitations

Our therapies enhance the clinical impact of immune checkpoint inhibitors and work where others fail:

Active Against Resistant Cells

Active against immunotherapy resistant cancer cells, overcoming prior treatment failures

Tumor Heterogeneity Independent

Tumor response is independent of tumor heterogeneity and mutational burden

Broad T-cell response

Ideal to combine with immune checkpoint inhibitors

Mechanism of Action

Our Unique Two-Step Mode of Action

Our oncolytic molecules work through a powerful dual mechanism that destroys tumors and activates lasting immunity.

Two-step mode of action - Cancer cell membrane destruction and immune activation

Tumor Destruction

Our oncolytic molecules destroy the membranes of cancer cells, causing rapid tumor necrosis and releasing tumor antigens and immunostimulatory molecules.

Immune Activation

The released antigens and danger signals initiate a broad immune cell response, resulting in robust T-cell infiltration and durable anti-tumor immunity.

Abscopal Effect

Activation of the systemic immune system leads to abscopal effects in distant metastases, demonstrating that anti-cancer immunity extends beyond the local injection site.

Publications and Posters

Publications

Frontiers in Immunology, March 2024

LTX-315 triggers anticancer immunity by inducing MyD88- dependent maturation of dendritic cells

Xiao-Qing Li, Takahiro Yamazaki, Tianzhen He, Md Masud Alam, Jia Liu, Anna L. Trivett, Baldur Sveinbjørnsson, Øystein Rekdal, Lorenzo Galluzzi, Joost J. Oppenheim and De Yang

Most Patients Won't Respond to Immune Checkpoint Inhibitors

Acquired Resistance

Tumor Heterogeneity

Limited T-cell Infiltration

Our Oncolytic Molecule Therapies Address These Limitations

Active Against Resistant Cells

Tumor Heterogeneity Independent

Broad T-cell response

Our Unique Two-Step Mode of Action

Tumor Destruction

Immune Activation

Abscopal Effect

Publications and Posters

Publications

LTX-315 triggers anticancer immunity by inducing MyD88- dependent maturation of dendritic cells

A strategy for raising response rates to immunotherapy - MedNous

LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells

Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors

Oncolytic peptides DTT-205 and DTT-304 induce complete regression and protective immune response in experimental murine colorectal cancer

Targeting Cancer Heterogeneity with Immune Responses Driven by Oncolytic Peptides

Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

LTX-315 sequentially promotes lymphocyte-independent and lymphocyte-dependent antitumor effects

Enhanced T-lymphocyte infiltration in a desmoid tumor of the thoracic wall in a young woman treated with intratumoral injections of the oncolytic peptide LTX-315: a case report

The Novel Oncolytic Compound LTX-401 Induces Antitumor Immune Responses in Experimental Hepatocellular Carcinoma

Tumor lysis with LTX-401 creates anticancer immunity

Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model

Iterative Design and in Vivo Evaluation of an Oncolytic Antilymphoma Peptide

Oncolytic peptide LTX-315 induces an immunemediated abscopal effect in a rat sarcoma model

LTX-315: a first-in-class oncolytic peptide that reprograms the tumor microenvironment

LTX-315, CAPtivating immunity with necrosis

The oncolytic compound LTX-401 targets the Golgi apparatus

The Cytolytic Amphipathic β(2,2)-Amino Acid LTX-401 Induces DAMP Release in Melanoma Cells and Causes Complete Regression of B16 Melanoma

The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade

Discovery of a 9-mer Cationic Peptide (LTX-315) as a Potential First in Class Oncolytic Peptide

The oncolytic peptide LTX-315 triggers immunogenic cell death

The oncolytic peptide LTX-315 triggers necrotic cell death

The oncolytic peptide LTX-315 induces cell death and DAMP release by mitochondria distortion in human melanoma cells

The oncolytic peptide LTX-315 kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization

LTX-315 (Oncopore™) – A short synthetic anticancer peptide and novel immunotherapeutic agent

Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315

Oral presentation at AASLD, The Liver Meeting 2013

Relative spatial positions of tryptophan and cationic residues in helical membrane-active peptides determine their cytotoxicity

Small lytic peptides escape the inhibitory effect of heparan sulfate on the surface of cancer cells

Therapeutic vaccination against a murine lymphoma by intratumoral injection of a cationic anticancer peptide

The anticancer activity of lytic peptides is inhibited by heparan sulfate on the surface of the tumor cells

The antimicrobial peptide, Lactoferricin B, is cytotoxic to neuroblastoma cells in vitro and inhibits xenograft growth in vivo

The effects of shortening lactoferrin derived peptides against tumor cells, bacteria and normal human cells

Enhanced antitumor activity of 15-residue bovine lactoferricin derivatives containing bulky aromatic amino acids and lipophilic N-terminal modifications

Antitumor activity and specificity as a function of substitutions in the lipophilic sector of helical lactoferrin-derived peptides

Enhanced antitumor activity and selectivity of lactoferrin derived peptides

Evidence for a Direct Antitumor Mechanism of Action of Bovine Lactoferricin

Posters

Exploratory Analysis of a Phase 2 Multicenter Study Evaluating Local Immune Activation in the Tumor Microenvironment 12 Weeks Post ruxotemitide (VP-315), an Investigational Therapy for Basal Cell Carcinoma (BCC)

Intratumoral injection of LTX-315 in combination with Pembrolizumab in patients with advanced melanoma refractory to prior PD-1/PD-L1 therapy: Interim results from the ATLAS-IT-05 trial

Molecular mechanisms of DC activation by melanoma cells responding to LTX-315

LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes in patients with metastatic soft tissue sarcoma (ATLAS-IT-04)

Immunotherapeutic and antimetastatic activity of LTX-315 in preclinical models of ICI-resistant breast cancer

LTX-401 as a novel antitumor and immunotherapeutic agent in an experimental liver cancer model

A phase I study of the oncolytic peptide LTX-315 generates de novo T-cell responses and clinical benefit in patients with advanced melanoma

A phase I study of the oncolytic peptide LTX-315 generates de novo T-cell responses and clinical benefits in patients with advanced sarcoma

A Phase I/II study of the oncolytic peptide LTX-315 combined with checkpoint inhibition generates de novo T-cell responses and clinical benefit in patients with advanced solid tumors

LTX-315: A first-in-class oncolytic peptide that reshapes the tumor microenvironment

LTX-315, a first in class oncolytic peptide, reshapes the tumor microenvironment in the patients with advanced metastatic tumors: Results from an ongoing study

LTX-315, a first in class oncolytic peptide reshapes the tumor microenvironment in the majority of patients with advanced metastatic tumors: Results from an ongoing clinical phase I study

LTX-315: A first-in-class oncolytic peptide that reshapes the tumor microenvironment

LTX-315, a first in class oncolytic peptide reshapes the tumor microenvironment inducing a local and systemic effect in metastatic tumors: Results from an ongoing study

Induction of immunogenic cell death and tumor regression in murine animal models by a novel cytolytic compound, LTX-401

Mode of action study on LTX-315-induced cell death

A phase I, dose escalation study of LTX-315 as monotherapy or in combination with either ipilimumab or pembrolizumab, in patients with transdermally accessible tumors (NCTO 1986426)

The oncolytic peptide LTX-315 enhances T cell clonality and induces synergy with chemotherapy

The oncolytic peptide LTX-315 enhances T cell clonality and induces synergy with CTLA-4 blockade

The amphiphatic β(2,2)-amino acid LTX-401 induces complete regression of experimental hepatocellular carcinoma

The oncolytic peptide LTX-315 enhances tumor-specific immune responses and tumor regression in murine 4T1 breast cancer when combined with doxorubicin

LTX-315, an oncolytic peptide, increases anticancer immunity mediated by CTLA4 blockade in an interleukin-2 receptor beta-chain-dependent manner

Enhanced antitumor activity achieved by combining the oncolytic peptide LTX-315 with anti-PD-L1 antibody

Intra-tumoural treatment with LTX-315, an oncolytic peptide immunotherapy, in patients with advanced metastatic disease induces infiltration of CD8 effectors T-cells and regression in some injected tumors

Anticancer effects obtained against A20 lymphomas following treatment with LTX-315 (Oncopore™) in combination with low-dose cyclophosphamide

Complete and specific regression of disseminated tumors in a novel rat mesenchymal three-tumor model after intralesional treatment with the nonapeptide LTX-315 (Oncopore™)

A Phase I study with LTX-315 – an immunogenic cell death inducer – in patients with transdermally accessible tumors

LTX-315 treatment induces complete and specific regression of disseminated tumors in a novel mesenchymal three tumor model